Loading...
KD025 Shifts Pulmonary Endothelial Cell Bioenergetics and Decreases Baseline Lung Permeability
KD025 is a ROCK2 inhibitor currently being tested in clinical trials for the treatment of fibrotic lung diseases. The therapeutic effects of KD025 are partly due to its inhibition of profibrotic pathways and fat metabolism. However, whether KD025 affects pulmonary microvascular endothelial cell (PMV...
Na minha lista:
| Udgivet i: | Am J Respir Cell Mol Biol |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Thoracic Society
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7528923/ https://ncbi.nlm.nih.gov/pubmed/32628869 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1165/rcmb.2019-0435OC |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|